In similar manner as it was observed in CDDP-injured WT recipients (Figure 8; Figure S5), injection of Gal-3-/-DCsPam3CSK4 significantly aggravated renal failure in CDDP-treated Gal-3-/- recipients (Gal-3-/-Gal-3-/-DCsPam3CSK4) by promoting IFN-γ and IL-17-driven inflammation (Figure 9A-L; Figure S6). The gene discussed is IL17A; the disease is kidney failure.